Geneeskunde en Gezondheids­wetenschappen

OMICS Research Day

15 May 2024 - CDE, BuildingQ, D.Q.002

Pioneering the next wave of Biomedical Discovery

Wednesday 15 May 2024 
Time: 09:30 - 16:30
LocationCampus Drie Eiken, Promotiezaal D.Q.002 + Foyer

REGISTRATION- mandatory but free

PROGRAM:

09:30
INTRODUCTION
09:40
Centre for Proteomics: an overview of clinical mass spectrometry based proteomics infrastructure,
Inge Mertens
10:10
​Introduction of the Olink PEA technology
André Wijfjes, Field Application Scientist
10:40
BREAK
10:55
Kin2omics: guiding drug discovery and tailored cancer therapy selection by integrating multi-omic biomarker signatures with functional kinome activity profiling
Wim Vanden Berghe
11:25
Kinome2OMICS: a flexible platform for multi-omics data integration and target prioritization
Steven Van Laere
11:55
LUNCH
12:40
MALDI imaging in clinical research
Eline Berghmans
13:00
Liquid biopsy of the cochlea: challenges and opportunities
Vincent Van Rompaey
13:20
Small talk: acquiring biochemical insights through mass spectrometry-based metabolomics and lipidomics
Adrian Covaci
13:40
​Improved immunopeptidome analysis using timsTOF fragment ion intensity prediction
Wout Bittremieux
14:00
Questions
14:15
BREAK
14:30
Towards personalized medicine: Integrating organoid-based drug screening with multi-omics analysis
Maxim Le Compte
14:50
​Inducing neoantigens with cold atmospheric plasma to improve cancer immunotherapy
Jana Baroen
15:10
Molecular characterisation of EV-derived biomarkers in neurodegenerative conditions
Yaël Hirschberg
15:30
Questions
15:50
NETWORKING

Abstract

Kin2omics: guiding drug discovery and tailored cancer therapy selection by integrating multi-omic biomarker signatures with functional kinome activity profiling

Wim Vanden Berghe
Cell Death Signaling Lab-IPPON, Department Biomedical Sciences, UAntwerp

Disease relapse and therapy resistance remain key challenges in cancer treatment. Underlying (epi-)mutational events typically promote tumorigenesis and contribute to multi-drug therapy resistance.  Although innovative biomarker “omic” strategies (genome-epigenome-transcriptome-proteome-metabolome-lipidome) are instrumental to optimize personalized precision oncology treatments, diagnostic signatures remain challenging due to (epi)genetic plasticity of (immunogenic) cell death signaling pathways and tumor-immune microenvironment heterogeneity, causing therapy escape, which prevents complete recovery and ultimately triggers disease relapse. Tailoring oncology treatments by multiplex, functional kinase activity profiling technology holds immense potential in overcoming the current challenges posed by cancer-tumor microenvironment heterogeneity to improve patient outcomes. Kinases are the most intensively studied protein targets and are the basis of numerous types of cancer therapies. However, the traditional -omic approaches study the abundance of proteins rather than their activity. This results in a knowledge gap on how cell signaling really works and a partial understanding of cancer drug mechanism of action (i.e. specificity, efficacy).  Phoshopeptidome based kinome activity phenotyping reveals the bigger picture of cellular signaling and provides mechanistic biological insights needed to fully understand cellular signaling bypasses upon therapy resistance.